Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Lupski Lab, |
RCV001172463 | SCV001241534 | likely pathogenic | Neurodevelopmental disorder | 2019-11-30 | no assertion criteria provided | research | |
OMIM | RCV002265938 | SCV002547467 | pathogenic | Dworschak-Punetha neurodevelopmental syndrome | 2022-07-13 | no assertion criteria provided | literature only | |
Prevention |
RCV004743286 | SCV005346684 | likely pathogenic | PLXNA1-related disorder | 2024-03-06 | no assertion criteria provided | clinical testing | The PLXNA1 c.1549C>T variant is predicted to result in premature protein termination (p.Gln517*). This variant was reported in the compound heterozygous state in three siblings with Dworschak-Punetha neurodevelopmental syndrome; the father and an additional sibling carried this variant alone and were unaffected (Dworschak et al. 2021. PubMed ID: 34054129). This variant is reported in 0.0023% of alleles in individuals of European (Non-Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/). Nonsense variants in PLXNA1 are expected to be pathogenic. This variant is interpreted as likely pathogenic for autosomal recessive disease. |